Clinical Trial Update: Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of panitumumab-IRDye800 in pancreatic adenocarcinoma patients undergoing surgery is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Panitumumab-IRDye800

Snippet

Sponsor: George Poultsides | Conditions: Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING